Stock IMCR IMMUNOCORE HOLDINGS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Immunocore Holdings plc

Equities

IMCR

US45258D1054

Real-time Estimate Cboe BZX
Other stock markets
 14:41:02 24/06/2024 BST 		5-day change 1st Jan Change
35.98 USD +0.15% Intraday chart for Immunocore Holdings plc -6.58% -47.41%
06-18 Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment MT
06-18 Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Immunocore : Corporate Presentation – June 2024
PU
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
GL
Immunocore : Earnings Release Q3 2023
PU
Immunocore : Earnings Release FY 2022
PU
Immunocore : Earnings Release Q1 2021
PU
Immunocore : Earnings Release Q1 2024
PU
Immunocore : Earnings Release Q2 2023
PU
Immunocore : Earnings Release Q1 2023
PU
Immunocore : Earnings Release FY 2021
PU
Immunocore : Earnings Release FY 2023
PU
Immunocore : Earnings Release Q3 2022
PU
Immunocore : Earnings Release Q2 2022
PU
Immunocore : Earnings Release Q1 2022
PU
Immunocore : Earnings Release Q3 2021
PU
Immunocore : Earnings Release Q2 2021
PU
Immunocore : Earnings Release FY 2020
PU
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
AQ
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
GL
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
GL
Immunocore : PRAME Phase 1 Cutaneous Melanoma Data – ASCO 2024
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMCR Stock
  4. News Immunocore Holdings plc
  5. Press Releases